Spontaneous Reporting-UK

Pharmacovigilance: Second Edition

Volumn , Issue , 2007, Pages 199-215

  Davis, Sarah ^a   King, Bridget ^a   Raine, June M ^a  

^a MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

Author keywords

CSM drug safety bulletin Current Problems in Pharmacovigilance; Medicines and Healthcare products Regulatory Agency (MHRA); Spontaneous reporting United Kingdom (UK); Unlicensed complementary and alternative medicines; Widening Yellow Card reporting base

Indexed keywords

EID: 84889297221     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470059210.ch15     Document Type: Chapter

References (60)

1. Alvarez-Requejo A, Carvajal A, Begaud B et al. (1998) Under-reporting of adverse drug reactions. Estimate based on a spontaneous reporting scheme and a sentinel system. Eur J Clin Pharmacol 54: 483-8.
2. Always Read the Leaflet-Getting the best information with every medicine. Report of the Committee on Safety of Medicines Working Group on Patient Information (2005) London: The Stationery Office.
3. Amery WK (1999) Why there is a need for pharmacovigilance. Pharmacoepidemiology and Drug Safety 8: 61-4.
4. Anon (1996) Extension of Yellow Card Scheme to unlicensed herbal remedies. Current Problems in Pharmacovigilance 22: 10.
5. Anon (1997a) Pharmacists' adverse drug reaction reporting to start on April 1. Pharmacol J 258: 330-1.
6. Anon (1997b) Electronic yellow card in GP computer prescribing systems. Current Problems in Pharmacovigilance 23: 10.
7. Anon (1998a) HIV adverse drug reactions reporting scheme. Current Problems in Pharmacovigilance 24: 3.
8. Anon (1998b) HIV ADR reporting scheme. The first seven months. HIV ADR Reporting Scheme News August 1998: 1.
9. Anon (1999) 'Yellow card' reporting now allowed for all community pharmacists. Pharmacol J 263: 776.
10. Anon (2000a) An updated Yellow Card for the new millennium. Current Problems in Pharmacovigilance 26: 12.
11. Anon (2000b) Updated 'yellow card' launched. Pharmacol J 265: 387.
12. Anon (2000c) Yellow card updated to protect privacy. Scrip 2575: 6.
13. Anon (2000d) Reminder: St John's wort (Hypericum perforatum) interactions. Current Problems in Pharmacovigilance 26: 6-7.
14. Anon (2003) Kava-kava and hepatotoxicity. Current Problems in Pharmacovigilance 29: 8.
15. Anon (2004) Black cohosh (cimicifuga racemosa) and hepatotoxicity. Current Problems in Pharmacovigilance 30: 10.
16. Bateman DN, Sanders GLS, Rawlins MD (1992) Attitudes to adverse drug reaction reporting in the Northern Region. Br J Clin Pharmac 34: 421-6.
17. Belton KJ, Lewis SC, Payne S et al. (1995) Attitudinal survey of adverse drug reaction reporting by medical practitioners in the United Kingdom. Br J Clin Pharmacol 39: 223-6.
18. Chan TYK, Critchley JAJH (1994) Reporting of adverse drug reactions in relation to general medical admissions to a teaching hospital in Hong Kong. Pharmacoepidemiology and Drug Saf. 3: 85-9.
19. Davis S, Coulson R (1999) Community pharmacist reporting of suspected ADRs: (1) The first year of the yellow card demonstration scheme. Pharmacol J 263: 786-8.
20. Davis S, Coulson RA, Wood SM (1999) Adverse drug reaction reporting by hospital pharmacists: the first year. Pharmacol J 262: 366-7.
21. DIRECTIVE 2004/24/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 31 March 2004 amending, as regards traditional herbal medicinal products, Directive 2001/83/EC on the Community code relating to medicinal products for human use. Official Journal of the European Union.
22. Edwards IR (1997) Adverse drug reactions: finding the needle in the haystack. Br Med J 519: 500.
23. Eland IA, Belton KJ, van Grootheest AC et al. (1999) Attitudinal survey of voluntary reporting of adverse reactions. Br J Clin Pharmacol 48: 623-7.
24. Ernst E, White A (2000) The BBC survey of complementary medicine in the UK. Complementary Therapies in Medicine 8: 32-6.
25. Evans SJ, Waller PC, Davis S (2001) Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmcoepidemiol Drug Saf 10(6): 483-6.
26. General Medical Council (2000) Confidentiality: protecting and providing information. www.gmc-uk.org/standards/standards-framework.htm.
27. Griffin JP (1986) Survey of the spontaneous adverse drug reaction reporting schemes in fifteen countries. Br J Clin Pharmacol 22: 83S-1005.
28. Griffin JP (1992) Medicines control within the United Kingdom. In: Griffin JP, ed., Medicines: Regulation, Research and Risk, 2nd edn. Belfast: The Queen's University.
29. Griffin JP, Weber JCP (1992) Voluntary systems of adverse reaction reporting. In: Griffin JP, ed., Medicines: Regulation, Research and Risk, 2nd edn. Belfast: The Queen's University.
30. Hall M, McCormack P, Arthurs N et al. (1995) The spontaneous reporting of adverse drug reactions by nurses. Br J Clin Pharmacol 40: 173-5. Health Service Circular 2000/026 Patient Group Directions [England Only].
31. Houghton J, Woods F, Davis S et al. (1999) Community pharmacist reporting of suspected ADRs: (2) Attitudes of community pharmacists and general practitioners in Wales. Pharmacol J 263: 788-91.
32. Houghton JE, Pinto Pereira LM, Woods FJ et al. (1996) The Welsh adverse drug reactions scheme: experience of a UK regional monitoring centre. Adverse Drug React Toxicol Rev 15: 93-107.
33. Haramburu F, Begaud B, Moride Y (1997) Temporal trends in spontaneous reporting of unlabelled adverse drug reactions. Br J Clin Pharmacol 44: 299-301.
34. Lawson DH (1990) The yellow card: mark II. Br Med J 301: 1234.
35. Lee A, Bateman DN, Edwards C et al. (1997) Reporting of adverse drug reactions by hospital pharmacists: pilot scheme. Br Med J 315: 519.
36. Leeder JS (1996) Developmental aspects of drug metabolism in children. Drug Inf J 30: 1135-43.
37. Mail (The MHRA updating service for medicines) (2005) Mandatory electronic Individual Case Safety Reports (ICSRs) reporting 150(July/August): 3-4.
38. Meyboom RHB, Egberts ACG, Edwards IR et al. (1997a). Principles of signal detection in pharmacovigilance. Drug Saf 16: 355-65.
39. Meyboom RHB, Hekster YA, Egberts ACG et al. (1997b). Causal or casual? The role of causality assessment in pharmacovigilance. Drug Saf 17: 374-89.
40. Moore N, Paux G, Begaud B et al. (1985) Adverse drug reaction monitoring: doing it the French way. Lancet 9(November): 1056-8.
41. Moride Y, Haramburu F, Requejo AA et al. (1997) Underreporting of adverse drug reactions in general practice. Br J Clin Pharmacol 43: 177-81.
42. Morrison-Griffiths S. (2000) Adverse drug reaction reporting by nurses. M Phil Thesis. University of Liverpool.
43. Morrison-Griffiths S, Walley TJ, Park BK et al. (2003) Reporting of adverse drug reaction by nurses. Lancet 361(April): 1347-8.
44. The NHS Plan-a plan for investment, a plan for reform. Presented to Parliament by the Secretary of State for Health by Command of Her Majesty (July 2000) HMSO © Crown Copyright 2000.
45. The NHS Plan-a progress report. The NHS Modernisation Board's Annual Report 2003.
46. Rawlins MD (1988a) Spontaneous reporting of adverse drug reactions I: the data. Br J Clin Pharmacol 26: 1-5.
47. Rawlins MD (1988b) Spontaneous reporting of adverse drug reactions II: uses. Br J Clin Pharmacol 26: 7-11.
48. Rawlins MD, Fracchia GN, Rodriguez-Farre E. (1992) EURO-ADR: Pharmacovigilance and research. A European perspective. Pharmacoepidemiol Drug Saf 1: 261-8.
49. Reed MD (1996) The ontogeny of drug disposition: focus on drug absorption, distribution and excretion. Drug Information J 30: 1129-34.
50. Report of an Independent Review of Access to the Yellow Card Scheme (April 2004) London: The Stationery Office © Crown Copyright 2004.
51. Roberts PI, Wolfson DJ, Booth TG (1994) The role of pharmacists in adverse drug reaction reporting. Drug Saf 11: 7-11.
52. Smith CC, Bennett PM, Pearce HM et al. (1996) Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. Br J Clin Pharmacol 42: 423-9.
53. Speirs CJ, Griffin JP, Weber JCP et al. (1984) Demography of the UK adverse reactions register of spontaneous reports. Health Trends 16: 49-52.
54. Sweis D, Wong ICK (2000) A survey on factors that could affect adverse drug reaction reporting according to hospital pharmacists in Great Britain. Drug Saf 23: 165-72.
55. Van den Bemt PML, Egberts ACG, Lenderink AW et al. (1999) Adverse drug events in hospitalized patients. A comparison of doctors, nurses and patients as sources of reports. Eur J Clin Pharmacol 55: 155-8.
56. Verity C, Preece M (2002) Surveillance for rare disorders by the BPSU. Archives of Disease in Childhood 87: 269-71.
57. Waller PC, Coulson RA, Wood SM (1996) Regulatory pharmacovigilance in the United Kingdom: current principles and practice. Pharmacoepidemiol Drug Saf 5: 363-75.
58. Waller PC, Evans SJ (2003) A model for the future conduct of pharmacovigilance. Pharmacoepidemiol Drug Saf 12(1): 17-29.
59. Wells TG (1996) Underserved therapeutic classes: examples which should not be ignored in infants and children. Drug Information J 30: 1179-86.
60. Wiholm B-E, Olsson S, Moore N et al. (1994) Spontaneous reporting systems outside the United States. In: Strom BL, ed., Pharmacoepidemiology, 2nd edn. Chichester: Wiley.